---
layout: page
title: Publications
description: My publications
keywords: Paper, Books
comments: true
menu: Publications
permalink: /publications/
---

## Peer-reviewed

`(#- equal contribution * - Corresponding author)`

<style>
</style>

1. `Jiang YZ#, Ma D#, Jin X#, Xiao Y#, Yu Y#, Shi J#`, Zhou YF, Fu T, Lin CJ, Dai LJ, Liu CL, Zhao S, Su GH, Hou W, Liu Y, **Chen Q**, Yang J, Zhang N, Zhang WJ, Liu W, Ge W, Yang WT, You C, Gu Y, Virginia Kaklamani, Fran√ßois Bertucci, Claire Verschraegen, Anneleen Daemen, Nakul M. Shah, Wang T, Guo T, Shi L, Charles M. Perou, `Zheng Y*, Huang W*, Shao ZM*`. Integrated omics refines the molecular portraits of breast cancer. ***Nature Cancer***. (**AIP**) 

2. `Jin X#, Zhou Y#, Ma D#, Zhao S#, Lin C#`, Xiao Y, Fu T, Liu C, Chen Y, Xiao W, Liu Y, **Chen Q**, Yu Y, Shi L, Shi J, Huang W, John FR Robertson, `Jiang YZ*, Shao ZM*`. Molecular Classification of Hormone Receptor-positive HER2-negative Breast Cancer. ***Nature Genetics***. 2023. PMID: 37770634

3. `Zheng Y#*, Liu Y#, Yang J#, Dong L#, Zhang R#, Tian S#`, Yu Y, Ren L, Hou W, Zhu F, Mai Y, Han J, Zhang L, Jiang H, Lin L, Lou J, Li R, Lin J, Liu H, Kong Z, Wang D, Dai F, Bao D, Cao Z, Chen QC,**Chen QW**, Chen X, Gao Y, Jiang H, Li B, Li B, Li J, Liu R, Qing T, Shang E, Shang J, Sun S, Wang H, Wang X, Zhang N, Zhang P, Zhang R, Zhu S, Scherer A, Wang J, Wang J, Huo Y, Liu G, Cao C, Shao L, Xu J, Hong H, Xiao W, Liang X, Lu D, Jin L, Tong W, `Ding C*, Li J*, Fang X*, Shi L*`. Multi-omics data integration using ratio-based quantitative profiling with Quartet reference materials. ***Nature Biotechnology***. 2023. PMID: 37679543

4. `Yu Y#, Hou W#, Liu Y#, Wang H#, Dong L#`, Mai Y, **Chen Q**, Li Z, Sun S, Yang J, Cao Z, Zhang P, Zi Y, Liu R, Gao J, Zhang N, Li J, Ren L,Jiang H, Shang J, Zhu S, Wang X, Qing T, Bao D, Li B, Li B, Suo C, Pi Y, WangX, Dai F, Scherer A, Mattila P, Han J, Zhang L, Jiang H, Thierry-Mieg D,Thierry-Mieg J, Xiao W, Hong H, Tong W, Wang J, Li J, Fang X, Jin L, `Xu J*,Qian F*, Zhang R*, Shi L*, Zheng Y*`. Quartet RNA reference materials improve the quality of transcriptomicdata through ratio-based profiling. ***Nature Biotechnology***. 2023. PMID: 37679545 

5. `Yu Y#, Zhang N#, Mai Y#,Ren L#`, Chen QC, Cao Z, **Chen QW**, LiuY, Hou W, Yang J, Hong H, Xu J, Tong W, Dong L, `Shi L*, Fang X*, Zheng Y*`. Correcting batcheffects in large-scale multiomics studies using a reference-material-basedratio method. ***Genome Biology***. 2023. PMID: 37674217

6. `Yang J#, Liu Y#, ShangJ#`, Chen QC, **Chen QW**, Ren L, Zhang N,Yu Y, Li Z, Song Y, Yang S, Scherer A, Tong W, Hong H, Shi L, Xiao W, Zheng Y*. The Quartet DataPortal: integration of community-wide resources for multiomics quality control. ***Genome Biology***. 2023. PMID: 37884999

7. `**Chen Q#**, Guo X#, Wang H#`, Sun S, Jiang H,Zhang P, Shang E, Zhang C, Niu Q, Cao Z, Zhang R, Liu Y, Shi L, `Yu Y*, Hou W*,Zheng Y*`. Plasma-free blood samples are potential alternatives to whole blood samples for transcriptome analysis. ***Phenomics***. 2023. https://link.springer.com/article/10.1007/s43657-023-00121-1

8. `Shang E#, Sun S#, ZhangR#`, Cao Z, **Chen Q**, Shi L, Wu J, `Wu S*, LiuY*, Zheng Y*`. Overexpression of CD99 is associated with tumor adaptiveness andindicates the tumor recurrence and therapeutic responses in gliomas. ***Translational Oncology***. 2023. PMID: 37579711

9.  Liu Y, Lin Z, **Chen QW**, Chen QC, Sang L, Wang Y, Shi L, `Guo L*, Yu Y*`. PAnno: A pharmacogenomics annotation tool for clinical genomic testing. ***Frontiers in Pharmacology***. 2023. PMID: 36778023

10. `**Chen Q#**, Liu Y#, Gao Y#, Zhang R#, Hou W#`, Cao Z, Zheng Y, Shi L, Jiang Y, `Ma D*, Yang J*, Shao Z*, Yu Y*`. A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers. ***Scientific Data****.* 2022. PMID: 36153392

11. `Ran Z#*, Yang J#, Liu Y#`, Chen X, Ma Z, Wu S, Huang Y, Song Y, Gu Y, Zhao S, Fa M, Lu J, **Chen Q**, Cao Z, Li X, Sun S. GlioMarker: an integrated database for knowledge exploration of diagnostic biomarkers in gliomas. ***Frontiers in Oncology***. 2022. PMID: 36081550

# Submitted or in preparation

`(#- equal contribution * - Corresponding author)`

1. `Liu Y#, **Chen QW#**`, Chen QC, Sang L, Wang Y, Shi L, Zheng Y, `Guo L*, Yu Y*`. A personal omics interpreter based ongenomic and transcriptomic profiles for comprehensive prioritization ofanti-cancer drugs. ***Science China Life Sciences***. (Under Preparation)

2. `Ruolan Zhang#, Shuai Wu#, Lin Chen#, Zehui Cao#`, Erfei Shang, Chen Luo, Shanyue Sun, Shangchen Xu, Weicheng Zheng, Qingwang Chen, Yang Ming, Leming Shi, `Yuanting Zheng*, Yingchao Liu*, Jinsong Wu*`. Temozolomide Harms IDH-wildtype and MGMT-p Unmethylated Histologic Grade 2 Adult Diffuse Glioma Patients. ***Clinical and Translational Medicine***. (In Review)

3. `Ouyang B#, Shan C#, ShenS#`, Dai X, **Chen Q**, Su X, Cao Y, He Y,Li X, Wang S, Qin X, Xu R, Hu R, ShiL, Lu T, Yang W, `Peng S*, Zhang J*, Wang J*, Li D*, Pang Z*`. Targetomics-based intelligent compound drug discovery for pyroptosis therapy oftriple-negative breast cancer. ***Nature Communications.*** (In Review)

4. `Yu X#, Li X#, **Chen Q#**`, Wang S, Xu R, He Y, Qin X, Peng S,Zhang J, Shi L, `Zheng Y*, Pang Z*, Lu L*`. High intensity focused ultrasound-driven nanomotorfor effective ferroptosis-immunotherapy of TNBC. ***Advanced Science***. (In Review)

5. `Shang J#, Zhao Y#, JiangH#`, Yang J, Zhang N, Ren L, **Chen Q**,Yu Y, Shi L, `ChenH*, Zheng Y*`. Poor prognosis of stage I lung adenocarcinoma patients determinedby elevated expression over pre/minimally invasive status of COL11A1 and THBS2in the focal adhesion pathway. ***medRxiv***. 2021. (***Cancer Communications***, **In Review.**)
